ERAS Quote, Financials, Valuation and Earnings

Atea Pharmaceuticals, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of --. Erasca, Inc.'s return on equity of -32.03% beat Atea Pharmaceuticals, Inc.'s return on equity of -36.97%.

Erasca, Inc. has a consensus price target of $5.13, signalling upside risk potential of 47.27%. On the other hand Atea Pharmaceuticals, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 64.38%. Given that Atea Pharmaceuticals, Inc. has higher upside potential than Erasca, Inc., analysts believe Atea Pharmaceuticals, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Atea Pharmaceuticals, Inc. has a beta of 0.159, suggesting its less volatile than the S&P 500 by 84.143%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atea Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Atea Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Atea Pharmaceuticals, Inc. quarterly revenues of --. Erasca, Inc.'s net income of -$30.6M is higher than Atea Pharmaceuticals, Inc.'s net income of -$42M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Atea Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 0.84x for Atea Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Foghorn Therapeutics, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of -194.4%. Erasca, Inc.'s return on equity of -32.03% beat Foghorn Therapeutics, Inc.'s return on equity of --.

Erasca, Inc. has a consensus price target of $5.13, signalling upside risk potential of 47.27%. On the other hand Foghorn Therapeutics, Inc. has an analysts' consensus of $11.67 which suggests that it could grow by 116.05%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Erasca, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Foghorn Therapeutics, Inc. has a beta of 3.043, suggesting its more volatile than the S&P 500 by 204.304%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Foghorn Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Foghorn Therapeutics, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Foghorn Therapeutics, Inc. quarterly revenues of $8.2M. Erasca, Inc.'s net income of -$30.6M is lower than Foghorn Therapeutics, Inc.'s net income of -$15.8M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Foghorn Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 13.46x for Foghorn Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of --. Erasca, Inc.'s return on equity of -32.03% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Erasca, Inc. has a consensus price target of $5.13, signalling upside risk potential of 47.27%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 861.08%. Given that GT Biopharma, Inc. has higher upside potential than Erasca, Inc., analysts believe GT Biopharma, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. Erasca, Inc.'s net income of -$30.6M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Prelude Therapeutics, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of -303.46%. Erasca, Inc.'s return on equity of -32.03% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.

Erasca, Inc. has a consensus price target of $5.13, signalling upside risk potential of 47.27%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 63.27%. Given that Prelude Therapeutics, Inc. has higher upside potential than Erasca, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 1.065, suggesting its more volatile than the S&P 500 by 6.517%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. Erasca, Inc.'s net income of -$30.6M is lower than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 16.52x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.